Taiwan Rule To Buy Only Local H1N1 Vaccine Criticized By Experts
This article was originally published in PharmAsia News
Executive Summary
Taiwan's decision to buy an H1N1 vaccine from the only local vaccine maker without also importing the drug is facing criticism by some experts. The government's bid system for purchases drew only one bidder, Taiwan's Adimmune, one-fifth owned by the government. Adimmune has relatively little experience compared with many foreign makers, and has yet to begin human trails on its version. The new purchase order given the company by the government seeks another 5 million doses. (Click here for more
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.